About Genetic Analysis AS

Genetic Analysis AS (GA) is a scientific-based Norwegian company, pioneer in the human microbiota field with over 10 years of expertise in microbiota analysis. GA was founded in 2008, based on the research work of Professor Knut Rudi from the Norwegian University of Life Sciences, Ås, Norway. GA consists of 21 highly qualified employees with relevant scientific backgrounds and with competence in bioinformatics, molecular biology and bioengineering.

GA is a fast-growing molecular diagnostic company which uses its unique, patented, and documented GA-map®technology to map gut microbiota by detecting and characterizing imbalance in the gut microbiota (dysbiosis) in human fecal samples.

We have core competence in detecting microorganisms like bacteria and viruses in stool and have the ability to develop In Vitro Diagnostic tests in all diseases where microbiota is involved. We are the first company in the world to develop, document, clinically validate and commercialize a CE-marked In Vitro Diagnostic test (GA-map® Dysbiosis Test Lx) for diagnosis and characterizing of dysbiosis in IBS and IBD patients. Our test has been used in 50 clinical trials and reported in 25+ scientific publications. In 2020 we launched the first CE-marked GA-map® COVID-19 fecal test. A Qualitative Real Time PCR test for the detection of the 2019 novel coronavirus (SARS-CoV-2) RNA in stool samples.